Today: 28 June 2026
Browse Category

NYSE:ABBV 4 February 2026 - 27 June 2026

AbbVie-Apogee deal on radar for US healthcare stocks next week

AbbVie-Apogee deal on radar for US healthcare stocks next week

AbbVie is reportedly nearing a $10.9 billion cash takeover of Apogee Therapeutics, offering a roughly 60% premium to Apogee’s Thursday close, with an announcement possible Monday; the deal puts both stocks at the center of Monday’s healthcare sector trading after a weak week for XLV, while risks remain as talks are unconfirmed and Apogee’s lead drug has not entered Phase 3 trials.
21 June 2026
··
AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

AbbVie shares closed Friday at $215.70, up 0.56%, gaining 2.5% for the week. The company reported a positive European panel recommendation for MAVIRET in acute hepatitis C and released new oncology data ahead of the ASCO meeting. U.S. markets are closed Monday for Memorial Day, with trading set to resume Tuesday.
23 May 2026
·
Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics reported its experimental psoriasis drug ORKA-001 achieved complete skin clearance in 63.5% of patients at 16 weeks. Shares jumped 10.5% to $76.39 before the company launched a $500 million public offering. No serious adverse events were reported in the trial. ORKA-001 is being developed as a long-acting injectable, with annual dosing possible.
27 April 2026
···
SCHD Draws Fresh Attention After New Dividend and 2026 Reconstitution

SCHD Draws Fresh Attention After New Dividend and 2026 Reconstitution

Schwab U.S. Dividend Equity ETF paid a $0.2569 per-share dividend for March, up 3.3% from last year, and finished a major reshuffle in its annual index reset. SCHD drew $4 billion in Q1 inflows as U.S. dividend funds saw their strongest start since 2020. The fund now holds 104 stocks, with Chevron and ConocoPhillips still its largest positions. Health care and tech exposure rose, while energy and materials fell.
6 April 2026
···········
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said its experimental obesity drug ABBV-295 led to up to 9.79% weight loss in adults over 12 weeks in a 76-patient phase 1 trial, with no serious adverse events reported. Weekly and less-frequent dosing schedules showed similar results, while placebo groups saw little change. The study population was mostly male with a mean BMI under 30. ABBV-295 is not approved and remains in early-stage testing.
10 March 2026
····
AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie shares closed up 1.8% at $231.50 Friday, outpacing Johnson & Johnson. U.S. markets will be closed Monday for Presidents Day, with trading set to resume Tuesday. Investors are weighing AbbVie’s drug-pricing moves and pipeline as the company shifts away from Humira after patent loss. Trading volume topped its recent average, with the stock about 5% below its 52-week high.
15 February 2026
··
AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie shares rose 0.7% to $224.83 Tuesday afternoon, near the session high, after BNP Paribas Exane raised its price target to $213 but kept a neutral rating. The stock traded in a narrow range as investors awaited delayed U.S. payrolls and inflation data for rate signals. U.S. stocks were mixed, with the Dow at a record high and S&P 500 little changed.
10 February 2026
··
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
7 February 2026
···
AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie shares climbed 2% to $223.45 in midday trading Friday after a volatile week. The move followed a quarterly report showing fourth-quarter net revenues up 10% to $16.62 billion and adjusted profit of $2.71 per share. Humira sales dropped 25.9% as biosimilar competition increased, while Skyrizi and Rinvoq posted gains. The company also announced new regulatory approvals and licensing deals.
6 February 2026
···
AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie shares rose 0.7% to $219.02 in after-hours trading Thursday, rebounding after a nearly 6% drop following its earnings report. Skyrizi beat sales estimates with $5.01 billion, while Rinvoq missed at $2.37 billion. The company raised its 2026 forecast for the pair to $31.6 billion. Investors remain focused on whether new drugs can offset Humira’s ongoing decline.
6 February 2026
···
AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie shares fell 3.9% in after-hours trading Wednesday after quarterly results showed Rinvoq sales missed expectations at $2.37 billion. Skyrizi sales beat forecasts at $5.01 billion, while Humira revenue dropped 25.9% to $1.25 billion. The company projected 2026 adjusted earnings above estimates, but investors focused on challenges replacing Humira as biosimilar competition grows.
5 February 2026
···
AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie shares fell 2.5% to $219.98 Wednesday after Rinvoq sales missed forecasts, despite the company raising its 2026 profit outlook. Q4 adjusted earnings reached $2.71 per share on $16.618 billion revenue; Skyrizi sales rose 32.5%, while Humira dropped 25.9%. AbbVie announced a three-year Medicaid pact with the Trump administration and pledged $100 billion in U.S. investments.
4 February 2026
···
1 2 3 … 6

Stock Market Today

  • Avino Silver & Gold Mines (TSX:ASM) Stock Review After Pullback and Valuation Analysis
    June 28, 2026, 11:02 AM EDT. Avino Silver & Gold Mines (TSX:ASM) shares have declined 4% in the past week and 13.4% over the last month, despite rising 8.1% year-to-date and 86.2% over the past year. The stock's volatility reflects its exposure to the precious metals sector amid broader materials market fluctuations. Simply Wall St's valuation rates Avino at 2 out of 6, signaling caution. However, a Discounted Cash Flow (DCF) analysis, projecting free cash flows through 2035, estimates an intrinsic value of $13.43 per share, suggesting the stock is undervalued by about 34.7%. Investors should weigh these conflicting valuation signals when considering Avino's potential. The company's recent financial performance and sector dynamics remain key factors in its outlook.

Latest articles

Intel (NASDAQ:INTC) edges lower, pulling back from $700 billion mark

Intel (NASDAQ:INTC) edges lower, pulling back from $700 billion mark

28 June 2026
Intel shares plunged 9.3% from Monday’s 52-week high, erasing $66 billion in market value and falling back below the $700 billion threshold as chip stocks tumbled on AI spending worries, with trading volume far outpacing short interest and sector profitability questions intensifying.
Ondas (NASDAQ:ONDS) drops 15% in volatile week after resale filing

Ondas (NASDAQ:ONDS) drops 15% in volatile week after resale filing

28 June 2026
Ondas Inc. (NASDAQ:ONDS) plunged 15.5% last week to $7.83 despite joining the Russell 3000 Index and announcing $40M+ in new defense orders; a June 26 filing registered 3.38M acquisition shares for resale, equal to 0.64% of shares, setting up a key test of real demand versus supply as index-driven volume fades ahead of the July 3 market holiday.
NVDA selloff drags $74 billion equity stake into spotlight

NVDA selloff drags $74 billion equity stake into spotlight

28 June 2026
Nvidia plunged 8.6% last week to $192.53, wiping out about $443 billion in equity value, as chip stocks suffered their worst week since April and Nvidia’s massive equity investment book added new risk to quarterly results; a further drop to $189.23 would mark a 20% slide from its May high.
Go toTop